Detecting minimal residual disease may be key to preventing ovarian cancer recurrence
August 27, 2025
Key takeaways:
- Women who had minimal residual disease following first-line ovarian cancer treatment had significantly worse OS.
- Many women who appeared in remission had surgically- or ctDNA-detected minimal residual disease.
UPDATES AND NEWS
Radical Collaboration: A Cancer Funder Seeks to Solve the Problem of Siloed Research | Inside Philanthropy
Why some family offices are becoming cancer research’s new bankrollers | Crain Currency
𝖡𝗋𝖾𝖺𝗄 𝘛𝘩𝘳𝘰𝘶𝘨𝘩 𝖢𝖺𝗇𝖼𝖾𝗋’𝗌 Tyler Jacks: “We’ve created a new operating model for collaborative cancer research. | The Cancer Letter
2025 Year in Review: Our Scientific Progress and Clinical Impact
BE PART OF THE MISSION
Stay Informed, Make an Impact
Subscribe
Be the first to hear about cutting-edge research, pioneering projects, and the latest advancements in Break Through Cancer science. Sign up to stay informed.
Give
Your contribution fuels groundbreaking research in some of the most challenging cancers. Every gift accelerates progress. For more information please contact Michaela Forand at MF@breakthroughcancer.org or 1-800-757-9881 ext 2.
